Business Wire

Six Upgrades to Guarantee L4 Self-Driving Operation! RoboSense Upgraded 128-beam LiDAR RS-Ruby Plus

Share

RoboSense , a world-leading provider of Smart LiDAR Sensor Systems launched upgraded 128-beam LiDAR, RS-Ruby Plus , designed for autonomous driving commercial operation, and it debuted at CES2022. Nowadays, it obtained a large number of orders from multiple autonomous vehicle companies worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005763/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

RS-Ruby Plus (Photo: Business Wire)

Breaking through the limitations of the previous generation RS-Ruby,the RS-Ruby Plus adopts a new modular architecture design, which reduces its size and weight by 50% compared with the previous generation, and reduces power consumption to 30W, which is 33% lower than RS-Ruby. In the past two years, RS-Ruby has supported Momenta, IdriverPlus, DeepRoute.ai, AutoX, Mushroom Car Alliance and over thousands RoboTaxi fleets in pilot commercial operations with its stable and reliable operation performance.

Six Upgrades of RS-Ruby Plus:

1. Automotive-grade design for reliability as the reference

RoboSense developed a new architecture design for RS-Ruby Plus with reference to automotive-grade standards to ensure that the product passes tens of automotive-grade reliability tests including mechanical shock, random vibration, low temperature operation, high-pressure water impact and EMC.
Watch:RS-Ruby Plus passed dozens of reliability tests

2. Comprehensively improve the perception distance

RoboSense achieved a breakthrough in the detection range of 905nm LiDAR on the premise of ensured safety of human eyes. The product reached a super detection range of 240m @10% standard reflectivity (under 100,000 Lux sunlight environment) and the overall detection range performance improved by 20%.

In the high-performance mode, Ruby Plus can increase the horizontal angular resolution of 128 channels from 0.2° to 0.1° at 10Hz refresh rate, thus providing more point cloud information in the horizontal direction. Meanwhile, 104 channels 0.1° vertical resolution, including 32 channels ultra-long detection range. RS-Ruby Plus detects cars at 218 meters with 4 lines and 13 points.
Watch:RS-Ruby Plus point cloud in various scenarios

3. Detection capability of black-painted vehicles boosted

Empowered by the super detection range capability, RS-Ruby Plus greatly improving the detection and recognition capabilities of perception for black vehicles.

The road line detection capability of RS-Ruby Plus has been improved, it stably detects 85-90 meters, thus further improving the safety and user experience of autonomous vehicles when changing lanes and going up and down ramps.

4. Higher accuracy and finer imaging

Detection range accuracy improvement of RS-Ruby Plus

  • Near-field area 0.4~3m, accuracy up to ±3cm (@100,000 Lux lighting environment)
  • Far-field area 3~240m, accuracy up to ±2cm (@100,000 Lux lighting environment)

The higher accuracy of LiDAR, the more precise and clear the shape of small objects like stone piers, lampposts and traffic cones can be restored.

5. Comprehensive anti-interference

RS-Ruby Plus uses the latest laser encryption technology, RS-Ruby Plus effectively resists interference from other LiDARs and ambient light and sunlight (100,000 Lux lighting).

6. Automotive Ethernet, gPTP, PTP

RS-Ruby Plus has automotive Ethernet interface. The product supports both GPS synchronization and network synchronization (PTP and gPTP time synchronization) protocols, which greatly reduces data transmission delay and simplifies cable layout.

RoboSense will always employ more advanced technology innovations and feature ever superior performance to empower industry partners, support the comprehensive commercialization of autonomous driving.

Read More: RoboSense Upgraded 128-beam LiDAR RS-Ruby Plus

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Grace Ye
Media@robosense.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye